Compugen Ltd. (NASDAQ:CGEN) Shares Bought by Atom Investors LP

Atom Investors LP grew its holdings in shares of Compugen Ltd. (NASDAQ:CGEN) by 27.5% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 151,816 shares of the biotechnology company’s stock after acquiring an additional 32,701 shares during the period. Atom Investors LP’s holdings in Compugen were worth $275,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the business. ARK Investment Management LLC grew its stake in shares of Compugen by 4.7% during the second quarter. ARK Investment Management LLC now owns 1,088,271 shares of the biotechnology company’s stock valued at $1,850,000 after acquiring an additional 48,979 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Compugen by 82.7% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 274,335 shares of the biotechnology company’s stock valued at $497,000 after acquiring an additional 124,190 shares in the last quarter. Rothschild Investment LLC acquired a new stake in shares of Compugen during the second quarter valued at about $380,000. Squarepoint Ops LLC lifted its position in shares of Compugen by 23.4% during the second quarter. Squarepoint Ops LLC now owns 85,693 shares of the biotechnology company’s stock worth $144,000 after purchasing an additional 16,253 shares during the last quarter. Finally, Joel Isaacson & Co. LLC lifted its position in shares of Compugen by 136.4% during the third quarter. Joel Isaacson & Co. LLC now owns 52,000 shares of the biotechnology company’s stock worth $94,000 after purchasing an additional 30,000 shares during the last quarter. 12.22% of the stock is currently owned by institutional investors and hedge funds.

Compugen Stock Performance

Shares of CGEN stock opened at $1.59 on Thursday. Compugen Ltd. has a one year low of $0.71 and a one year high of $3.03. The company’s 50-day simple moving average is $1.66 and its 200-day simple moving average is $1.82. The stock has a market capitalization of $141.89 million, a price-to-earnings ratio of 77.00 and a beta of 2.59.

Compugen (NASDAQ:CGEN) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.21 by ($0.20). Compugen had a return on equity of 2.62% and a net margin of 2.67%. The business had revenue of $17.13 million during the quarter, compared to the consensus estimate of $17.67 million. During the same period in the prior year, the business earned ($0.11) EPS. As a group, research analysts forecast that Compugen Ltd. will post 0.11 EPS for the current year.

Analysts Set New Price Targets

Separately, StockNews.com raised shares of Compugen from a “hold” rating to a “buy” rating in a research report on Thursday, August 15th.

Compugen Company Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.